Medicare could save hundreds of millions of dollars a year if everyone used the cheaper drug, Avastin, instead of the costlier one, Lucentis.
如果每个人都使用更便宜的药物安维汀，而不是更昂贵的雷珠单抗，那么医疗保障每年就可以节省数亿美元。
The Food and Drug Administration has not approved Avastin for use in the eye, and using it rather than the alternative, Lucentis, might carry an additional, although slight, safety risk.
美国食品和药品管理局还没有批准阿瓦斯汀用于眼部治疗，使用它来代替雷珠单抗可能会产生额外的安全风险，尽管这一风险也许很轻微。
The FDA is also concerned that Avastin has bad side effects.
FDA也注意到阿伐斯汀有坏的副作用。
About 2% of women in the study on chemo plus Avastin died, whereas no one who got chemotherapy alone did.
研究中大约2 %左右的妇女接受化疗和阿伐斯汀联用治疗时死了，但没有一个人单接受化疗而死亡。
Some doctors on their own already use Avastin to treat breast cancer, in a so-called off-label use of the drug. But F.
有些医生已经以一种所谓超出该药药物说明书列出的应用范围方式将这种药应用到乳腺癌治疗。
Now that the FDA has formally withdrawn the breast cancer indication for Avastin, still more debate is likely to break out.
现在，美国食品和药物管理局正式撤销安维汀治疗的乳腺癌适应症，更多的争论很可能会爆发。
The median survival for patients taking both Avastin and Gemzar was 5.7 months compared with 6.0 months for patients taking Gemzar alone.
吉西他滨合用贝伐单抗的患者中位生存期为5.7个月，而单用吉西他滨者为6个月。
The study researchers assigned 302 patients to receive Avastin and Gemzar and assigned an additional 300 patients to receive Gemzar plus placebo.
该研究中，302名患者接受吉西他滨合用贝伐单抗，300名患者接受吉西他滨和安慰剂。
Late last month, federal drug regulators gave their answer when they approved a drug called Avastin for treatment of patients with advanced breast cancer.
上个月底，联邦药品监管机构给予他们的答案时，他们批准了一项所谓的药物阿瓦斯丁用于治疗晚期乳腺癌。
Avastin currently is approved by the U.S. Food and Drug Administration (FDA) for treating lung and colon cancer, but many doctors use it to treat breast cancer.
阿瓦斯汀目前被美国食品和药物管理局(FDA)批准用于治疗肺癌和结肠癌，但许多医生将其用于治疗乳癌。
Although the study was not designed to compare the Avastin doses, a similar treatment effect in progression-free survival was observed between the two arms.
虽然这项研究并不是用来比较阿瓦斯丁剂量，一项类似的治疗效果，在级数无生存观察到两国之间的武器。
So, Winer said, it made perfect sense to him that Avastin should be approved for use in advanced breast cancer based on its ability to halt the progress of tumors.
所以，温特说，它取得了完美的责任感在他看来，阿瓦斯丁应当批准用于治疗晚期乳腺癌根据其能力，以制止进步的肿瘤。
The primary objective of the study was to demonstrate superiority in progression-free survival of both Avastin containing treatment arms versus the control regimen.
这项研究的主要目的是，要表现出优势，循序渐进无生存的阿瓦斯丁都含有治疗武器银两控制水情。
Though 10 of the 61 patients who suffered adverse reactions from receiving Avastin injections have recovered, the source and use of the controversial drug is still unknown.
在61名注射了阿瓦斯丁后有不良反应的患者中，虽然有10名已经恢复，但这种有争议的药物的来源和用途仍然处于未知状态。
Genentech is seeking approval of Avastin as a combination treatment with the chemotherapy drug paclitaxel in women with advanced breast cancer who haven't had chemo before.
基因泰克是寻求批准阿伐斯汀在患者没有接受化疗之前，作为一个与化疗药物紫杉醇联用来治疗晚期乳腺癌妇女。
Avastin is a laboratory-produced molecule known as a monoclonal antibody that mimics the antibodies produced by the body's immune system to defend against harmful substances.
阿瓦斯汀是一种实验室内生产的分子物质，也就是众所周知的单克隆抗体，它能够模拟机体免疫系统产生的抗体来抵御有害物质。
Axitinib was designed to block the creation of blood vessels that feed tumors, similar to Genentech Inc. 's (DNA) Avastin, which is used to treat colorectal and lung cancers.
阿西替尼通过抑制肿瘤血管的生成来起到抗癌的作用，与基因技术公司开发的阿瓦斯丁（该药物用于治疗结肠癌和肺癌）类似。
The most serious side effects associated with Avastin, in some cases resulting in death, are gastrointestinal perforation, wound healing complications, hemorrhage, and blood clots.
阿瓦斯汀最严重的副作用（这些副作用有时可以导致死亡）有胃肠穿孔，伤口愈合并发症，出血和血块形成。
The study found that in patients taking Avastin with another drug, Taxol, tumors stopped growing, on average, for 11.3 months, compared to 5.8 months among patients taking Taxol alone.
研究发现，在病人服用阿瓦·斯丁与另一药物，紫杉醇，肿瘤停止生长，平均11.3个月，相比5.8个月其中病人服用紫杉醇单。
"I think there are other agents out there that are available for this patient population," said Maha Hussain, chairwoman of FDA's oncology drugs advisory panel who voted against Avastin.
FDA肿瘤药物咨询委员会的MahaHussain，投票反对阿伐斯汀，他说：“我认为还有其他代替药物可供这类患者群使用。”
Most scientific experts consider this benefit "progression-free survival," sufficient for full approval, and many oncologists have been using Avastin as an "off-label" drug for this purpose.
多数的专家认为这得益于“无进展生存”，阿瓦斯丁已经被许多肿瘤学家作为“未贴签”药物用于治疗，足以完全通过审批。
Avastin is the first of this very exciting family of drugs to be approved for lung cancer, and there are several other drugs of this type under development which may prove to work even better.
阿瓦·斯丁是令人振奋的治疗肺癌药物家族中被核准的第一个药物，这个家族中还有一些其它的药物处于开发中，可能证实这些药物的药效会更好。
Avastin, in combination with intravenous 5-fluorouracil-based chemotherapy, was previously approved for first - or second-line treatment of patients with metastatic cancer of the colon or rectum.
阿瓦·斯丁与静脉注射5 -氟尿嘧啶为基础的化疗联合治疗，是早先被批准的用于治疗结肠或直肠的转移性的癌症患者的一线或二线用药。
Avastin, in combination with intravenous 5-fluorouracil-based chemotherapy, was previously approved for first - or second-line treatment of patients with metastatic cancer of the colon or rectum.
阿瓦·斯丁与静脉注射5 -氟尿嘧啶为基础的化疗联合治疗，是早先被批准的用于治疗结肠或直肠的转移性的癌症患者的一线或二线用药。
应用推荐